The study, sponsored by Université de Sherbrooke in collaboration with Eli Lilly and Chorus Wellness Inc., aims to establish the safety and biodistribution of the radiotracer [89Zr]Zr-DFO-AP-101 in both healthy volunteers and ALS patients. Given the lack of diagnostic tools for ALS, this asset has significant commercial potential as a first-in-class imaging biomarker that could enhance early detection and monitoring of disease progression. The ALS market is relatively underserved, with current diagnostic methods leading to misdiagnosis and delayed treatment. Successful outcomes from this trial could position [89Zr]Zr-DFO-AP-101 as a critical tool in neurology, potentially leading to partnerships or licensing opportunities with larger pharmaceutical companies focused on neurodegenerative diseases.